# \[e-drug\] MSF: TPP negotiators must fix most damaging trade agreement ever for global health

**URL:** <https://talk.edrugplus.org/t/e-drug-msf-tpp-negotiators-must-fix-most-damaging-trade-agreement-ever-for-global-health/41919>\
**Category:** e-drug\
**Created:** [July 24, 2015, 6:00pm UTC](https://talk.edrugplus.org/t/e-drug-msf-tpp-negotiators-must-fix-most-damaging-trade-agreement-ever-for-global-health/41919 "2015-07-24T18:00:46Z")\
**Posts on this page:** 1\
**Page:** 1

<div class="post-metadata">

**Author:** ![Michelle\_French](https://avatars.discourse-cdn.com/v4/letter/m/e495f1/32.png) [@Michelle\_French](https://talk.edrugplus.org/u/Michelle_French)\
**Post date:** [July 24, 2015, 6:00pm UTC](https://talk.edrugplus.org/t/e-drug-msf-tpp-negotiators-must-fix-most-damaging-trade-agreement-ever-for-global-health/41919/1 "2015-07-24T18:00:46Z")

</div>

E-DRUG: MSF: TPP negotiators must fix most damaging trade agreement ever for global health  
-----------------------------------------------

MSF PR issued today (24 July), as negotiations get underway in Hawaii:  
[http://www.msfaccess.org/about-us/media-room/press-releases/tpp-negotiators-must-fix-most-damaging-trade-agreement-ever](http://www.msfaccess.org/about-us/media-room/press-releases/tpp-negotiators-must-fix-most-damaging-trade-agreement-ever)

TPP Negotiators Must Fix the Most Damaging Trade Agreement Ever for Global  
Health

As U.S. aims to close deal, countries should reject damaging provisions  
that will block access to affordable medicines

Maui/New York, July 24, 2015 Trade negotiators must remove damaging access  
to medicines provisions in the Trans-Pacific Partnership (TPP) trade deal  
or risk locking in high drug prices and endangering the health of millions  
of people for decades to come, said the medical humanitarian organization  
Doctors Without Borders/Medecins Sans Frontieres (MSF) as negotiations  
resumed in Maui, Hawaii, today. MSF's call comes as reports indicate that  
this could be the last negotiation before the agreement is concluded.  
If approved in its current form, the TPP, which is being negotiated  
between the U.S. and 11 other Pacific Rim countries, will have a  
devastating impact on global health. It would strengthen, lengthen and  
create new patent and regulatory monopolies for pharmaceutical products  
that will raise the price of medicines and reduce the availability of  
price-lowering generic competition.

'We have raised our voice as loudly as we can, repeatedly warning that  
this is a terrible deal for access to affordable medicines,' said Manica  
Balasegaram, Executive Director of MSF's Access Campaign, 'Ministries of  
Health, humanitarian groups such as MSF and global health programs funded  
by the U.S. government all rely on affordable medicines to provide medical  
care. Despite repeated warnings from MSF, other concerned experts and  
groups, and even other negotiating countries, U.S. negotiators have pushed  
for provisions that benefit pharmaceutical companies at the expense of  
more than 800 million people who need access to affordable generic  
medicines in current TPP countries.'

Some of the most concerning provisions in the TPP center on so-called  
'patent evergreening,' which would force TPP governments to grant  
pharmaceutical companies additional patents for changes to existing  
medicines, even when those changes provide no therapeutic benefit to  
patients.

U.S. negotiators have also aggressively pushed for 12 years of 'data  
exclusivity' for biologic medicines, which include vaccines and drugs to  
treat conditions such as cancer and multiple sclerosis. Data exclusivity  
blocks government regulatory authorities from allowing price-lowering  
generic competitors to enter the market with previously generated clinical  
data.

If pharmaceutical companies get their way, brand-name drugs and vaccines  
would not face direct competition for excessively long periods of time  
while patients, medical providers like MSF, and people in TPP countries  
endure unnecessarily high prices.

'The U.S. is demanding that countries implement a devastating set of new  
trade rules that will essentially block people from benefitting from the  
latest advances in medicines for years simply because this is in the  
interest of multinational pharmaceutical companies,' said Judit Rius  
Sanjuan, U.S. Manager and Policy Advisor for MSF's Access Campaign.  
'Extended monopolies, such as those being pushed by the U.S. in the TPP,  
are irresponsible and harmful to public health.'

The provisions demanded by U.S. negotiators break past U.S. government  
commitments to global health, including a 2007 agreement in which the U.S  
agreed to include key public health safeguards in future free trade deals  
with developing countries.

'The U.S. has abandoned its previous commitments to protect health in its  
trade policy,' said Rius. 'The TPP is a precedent-setting blueprint for  
future trade deals that will deny countries their right to balance  
business interests with the public health needs of people ' a right that  
is ingrained in international trade rules. This week might be the last  
chance negotiators have to mitigate some of the potential devastation of  
the TPP. We ask government negotiators to protect access to medicines and  
fix the most damaging provisions in the TPP.'

Michelle French  
Sr. Communications Manager, MSF Access Campaign  
Doctors Without Borders\Médecins Sans Frontières (MSF)  
Office: +1.212.763.5735 | Mobile: +1.646.552.4600  
michelle.french@newyork.msf.org | Skype: michellejfrench  
www.msfaccess.org | twitter.com/MSF\_access | www.facebook.com/MSFaccess
